Baxter appeases EU regulators in $4B Gambro buyout

August 22, 2013 by Sony Salzman

The EU accepts Baxter's concessions over anti-monopoly concerns, allowing the $4B buyout of Swedish dialysis giant Gambro AB to go forward.

Baxter appeases EU regulators, closes $4B Gambro buyout

After months of negotiations with EuroZone regulators, Baxter's (NYSE:BAX) nearly $4 billion buyout of Swedish dialysis maker Gambro AB can go forward now that Baxter agreed to sell off its renal replacement therapy division to ease anti-trust concerns.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.